Q2 FY27 revenue rises 33% and EBITDA margin improves to 5.3%

Management guided margin improvementPromoter disclosed acquisition plansInvestor Communications View source PDF Explain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.6%Reaction day

₹1664.90

prior close

₹1682.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.1%+4.5% vs market

Retailing peers, median of 57sector · industry level+1.2%+4.4% vs sector

On the reaction day the stock moved 4.5 pts more than Nifty Microcap 250 and 4.4 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.5

10m

+3.7

15m

+3.8

30m

+4.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.6+1.1+4.5+1.2+4.4

Next day

+14.5pendingpending+0.9+13.6

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Entero’s Q2 FY27 revenue was Rs 2,087.1 crore, up 32.9% year on year. EBITDA rose 78% to Rs 110.7 crore as margin improved 135 basis points to 5.3%; profit to owners was Rs 45.5 crore. H1 operating cash flow was negative Rs 46.5 crore because of receivable timing; collections arrived in November. Management is on track for full-year guidance, plans to acquire smaller distributors, and expects FY27 MedTech revenue above Rs 1,000 crore.

Likely market impact

Strong growth and margin gains support shareholders, but negative H1 operating cash flow and higher borrowings remain key risks.